Coagulation factor concentrates and pharmacologic therapies for acquired bleeding disorders

Research output: Chapter in Book/Report/Conference proceedingChapter


Acquired bleeding disorders are much more common than congenital bleeding disorders and may occur in association with specific clinical conditions or may arise spontaneously in otherwise healthy patients. Prothrombin complex concentrates (PCCs) contain vitamin-K dependent coagulation factors (VKDFs) and are available as activated and nonactivated concentrates. Recombinant activated factor VII (rFVIIa) is a vitamin-K-dependent glycoprotein that initiates the tissue factor pathway of the coagulation cascade. At physiologic concentration, rFVIIa complexes with tissue factor (TF) at the site of vascular injury, forming the TF-FVIIa complex. Protamine sulfate is a strongly basic, arginine-rich protein that binds to the negatively charged heparin molecules forming an inactive salt, neutralizing heparin's anticoagulant effect within minutes. Idarucizumab is a humanized monoclonal Fab antibody fragment that binds dabigatran with a 350-fold higher affinity than thrombin, neutralizing its activity and reversing the anticoagulant effect within minutes.

Original languageEnglish (US)
Title of host publicationRossi's Principles of Transfusion Medicine
Number of pages10
ISBN (Electronic)9781119719793
ISBN (Print)9781119719755
StatePublished - Jul 10 2022


  • Acquired bleeding disorders
  • Idarucizumab
  • Protamine sulfate
  • Prothrombin complex concentrates
  • Recombinant activated factor
  • Tissue factor
  • Vitamin-kdependent coagulation factors

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Coagulation factor concentrates and pharmacologic therapies for acquired bleeding disorders'. Together they form a unique fingerprint.

Cite this